Fed. Circ. Agrees Purdue's OxyContin Patent Is Obvious
Law360 (April 4, 2019, 5:54 PM EDT) -- The only claim in a Purdue Pharma LP patent covering a way to make its OxyContin painkiller abuse deterrent doesn't hold up, the Federal Circuit said Thursday, affirming a Patent Trial and Appeal Board decision.
Purdue had argued in its appeal that the PTAB wrongly construed the patent and misinterpreted prior art, but after hearing oral arguments on Tuesday, the board affirmed the decision without further explanation.
The PTAB had invalidated the patent as obvious in November 2017 following a challenge by Amneal Pharmaceuticals LLC. Amneal was developing a generic with Kashiv Pharma, but later dropped out of the partnership —...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!